Preferred Drug List Committee Meeting
Meeting Minutes, Open Session
September 12, 2018 10:00 a.m.
DXC Technologies-Capital Room, 6511 SE Forbes Ave., Bldg. 283 J, Topeka, Kansas 66619

Board Members Present:

Taylor Gill, Pharm. D., BCPS (Interim Chair)	Megan Hedden, Pharm.D.	Raymond Magee, M.D. (Phone)
Donna Sweet, M.D. (Phone)	Wayne Wallace, M.D.	Robert Haneke, Pharm.D. (Phone)

Board Members Absent:

Emily Prohaska, PharmD, BCACP	Sharon Cain, M.D.

KDHE-DHCF Staff:

Annette Grant, RPh	Roxanne Chadwell, PharmD, CSP	Margaret O'Donnell, Transcriptionist

DXC/HID Staff Present:

Karen Kluczykowski, RPh.	Kathy Kaesewurm, R.N., BSN

MCOs Present:
Lisa Todd-Amerigroup

Public Attendees:
Melissa Basil, Larry Hill, AbbVie; Kristin Farmer, Brent Newell, Donna Belvitt, KDADS; Scott Brunner, Janet Grant, Aetna; Jason Lurk, Novo Nordisk; Rick Kegleng, Otsuka; Roy Lindfield, Sunovion; Chris Guenther, Genentech, Jim Baumann, Rob Hansen, AbbVie

Illegible names on sign-in sheet were not included.

Item	Facilitator (s)	Notes
I. Call to Order	Taylor Gill, Pharm.D., BCPS, AAHIVP	Dr. Gill called the September 12, 2018 PDL Committee meeting to order at 10:05 a.m.
II. Old Business **A. Review and Approval of June 13, 2018 Meeting Minutes.**	Taylor Gill, Pharm.D., BCPS, AAHIVP	The minutes for the June 13, 2018 PDL Committee meeting were not available for review at this time. Tabled to next meeting.
II. Old Business **B. Consent Agenda Items** i. PDL New Drug Placements 1. Aczone 7.5% gel 2. Avita Gel 3. Cleocin T-Swabs 4. Clindacin PAC 5. Differin Lotion, Solution 6. Ditropan Liquid 7. Evekeo 8. Fosamax Liquid 9. Retin-A 0.01% Gel 10. Sumadan XLT	Taylor Gill, Pharm.D., BCPS, AAHIVP	**Background:** At the September 12, 2018 PDL meeting the Committee agreed to the "Consent Agenda Items" old business." **Public Comment:** None. **Committee Discussion:** Dr. Sweet moved to approve. Dr. Wallace seconded the motion. The motion carried unanimously.

Item	Facilitator (s)	Notes
III. New Business **A. Acne Agents – Topical – Class Review – New Agent: (Altreno™)**	Taylor Gill, Pharm.D., BCPS, AAHIVP	**Background:** The Acne Agents – Topical class was first introduced to the PDL committee as a new class in May 2015 and was most recently reviewed in September 2015. This proposition is to request the inclusion of Altreno™. **Altreno™** was FDA approved in August 2018 and is a topical formulation of tretinoin, available as a 0.05% lotion. It is indicated for the treatment of acne vulgaris. A class comparison chart and package insert is included for the committee's review **Public Comment:** None**.** **Committee Discussion:** Dr. Wallace moved to approve. Dr. Magee seconded the motion. The motion carried unanimously.
III. New Business **B. ADHD – Methylphenidate Type – Class Review – New Agent: (Jornay PM™, Relexxii®, Methylphenidate ER 72 mg)**	Taylor Gill, Pharm.D., BCPS, AAHIVP	**Background:** The ADHD – Methylphenidate class was first introduced to the PDL committee as a new class in March 2017. This class was most recently reviewed in March of 2018 for the inclusion of Cotempla XR-ODT™. This proposition is to request the inclusion of **Relexxii®** and the generic form known as **Methylphenidate Extended Release 72mg tablet**. **Relexxii®** is a 72mg extended release, osmotic release tablet form of methylphenidate. Another product being proposed today for addition to the PDL is **Jornay PM™** (Methylphenidate ER). Jornay PM™ is designed to be taken before going to sleep, instead of immediately upon waking. An outer layer that delays the medication's release overnight to provide early-morning symptom control and controlled release throughout the day. A class comparison chart and package inserts are included for the committee's review. **Public Comment:** None. **Committee Discussion:** Dr. Haneke moved to approve. Dr. Wallace seconded the motion. The motion carried unanimously.

Item	Facilitator (s)	Notes
III. New Business **C. Antihistamine/Mast Cell Stabilizers – Ophthalmic – Class Review – New Agent: (Zerviate™)**	Taylor Gill, Pharm.D., BCPS, AAHIVP	**Background:** The Antihistamine/Mast Cell Stabilizers – Ophthalmic class was first introduced to the PDL committee as a new class in 2010 and was most recently reviewed in March of 2017. This proposition is to request the inclusion of **Zerviate™,** a topical ophthalmic formulation of cetirizine and is indicated for the treatment of ocular itching associated with allergic conjunctivitis. A class comparison chart and package inserts are included for the committee's review. **Public Comment:** None. **Committee Discussion:** Dr. Sweet moved to approve. Dr. Wallace seconded the motion. The motion carried unanimously.
III. New Business **D. ARBs – New Agent – (Prexxartan™)**	Taylor Gill, Pharm.D., BCPS, AAHIVP	**Background:** The ARB's class was first introduced to the PDL committee as a new class in November of 2002 and was most recently reviewed in March 2017. This proposition is to request the inclusion of **Prexxartan®**, an oral, liquid dosage form of valsartan. A class comparison chart and package inserts are included for the committee's review. **Public Comment:** None. **Committee Discussion:** There was committee discussion as to why this drug was not on the Consent agenda item list.The State replied that it was a different brand name than the current drug with the same generic name and it wasn't clear to the State that this option was allowed when the Consent Agenda Item criteria were initially approved. Dr. Haneke moved to approve. Dr. Wallace seconded the motion. The motion carried unanimously.

Item	Facilitator (s)	Notes
III. New Business **E. Beta-Blockers – New Agent (Kapspargo™Sprinkle)**	Taylor Gill, Pharm.D., BCPS, AAHIVP	**Background:** The Beta-Blockers class was first introduced to the PDL committee as a new class in November 2002 and was most recently reviewed in June 2017. This proposition is to request the inclusion of **Kapspargo™ Sprinkle,** which is an extended-release sprinkle formulation of metoprolol succinate whose contents may be sprinkled over soft food prior to administration. A class comparison chart and package inserts are provided for inclusion on the PDL. . **Public Comment:** None. **Committee Discussion:** Dr. Wallace moved to approve. Dr. Gill seconded the motion. The motion carried unanimously.
III. New Business **F. Corticosteroids – Oral – Class Review, new agents: (Cortef®, Cortone®, Decadron®, Dexamethasone Intensol®, Dexamethasone solution 0.5mg/5ml, Dexpak DP®, LoCort DP®, Medrol®, MedrolDP®, TaperDex DP®, Zodex DP®)**	Taylor Gill, Pharm.D., BCPS, AAHIVP	**Background:** The Corticosteroid – Oral products class was first introduced to the PDL committee as a new class in June 2018. This introduction approved the inclusion of oral formulations of prednisone and prednisolone. This proposition requests the inclusion of additional oral corticosteroids, including **cortisone**, **dexamethasone**, **hydrocortisone and methylprednisolone**. These agents are used to treat a variety of inflammatory conditions. A class comparison chart and package inserts are included for the committee's review. **Public Comment:** None. **Committee Discussion:** Committee member requested feedback on whether cortisone/hydrocortisone should be included since they are used for different indications. The Committee agreed to include them. Dr. Wallace moved to approve. Dr. Haneke seconded the motion. The motion carried unanimously.

Item	Facilitator (s)	Notes
III. New Business **G. Desmopressin Products – New Agent – (Nocdurna®)**	Taylor Gill, Pharm.D., BCPS, AAHIVP	**Background:** The Desmopressin products class was first introduced to the PDL committee as a new class in June 2018. This introduction approved the inclusion of Noctiva®, DDAVP®, and DDAVP® Rhinal Tube®. This proposition requests the inclusion **Nocdurna®**, an orally disintegrating tablet formulation of desmopressin; the man-made form of a naturally occurring hormone that regulates how the body uses water. A class comparison chart and package inserts are included for the committee's review. **Public Comment:** None **Committee Discussion:** Dr. Sweet moved to approve. Dr. Wallace seconded the motion. The motion carried unanimously.
III. New Business **H. Erythropoiesis Stimulating Agents – New Agent – (Retacrit™)**	Taylor Gill, Pharm.D., BCPS, AAHIVP	The Erythropoiesis Stimulating Agents class was first established in December 2008 and was most recently reviewed in June 2018 for the inclusion of Mircera®. This proposition is to request the inclusion of **Retacrit™** an injectable formulation of Epoetin Alfa Recombinant. Retacrit (epoetin alfa-epbx) is a biosimilar of Procrit® indicated for the treatment of anemia associated with chronic kidney disease and for the reduction of allogeneic RBC transfusion in patients undergoing elective, noncardiac, nonvascular surgery. A class comparison chart and package inserts are included for the committee's review. **Public Comment:** None. **Committee Discussion:** Dr. Wallace moved to approve. Dr. Haneke seconded the motion. The motion carried unanimously.

Item	Facilitator (s)	Notes
III. New Business **I. Immunomodulation Agents – Adult Rheumatoid Arthritis: New Agent – (Olumiant®)**	Taylor Gill, Pharm.D., BCPS, AAHIVP	**Background:** The Immunomodulation Agents – Adult Rheumatoid Arthritis class was first introduced to the PDL committee as a new class in March 2017. This class was most recently reviewed in June 2017 for the inclusion of Kevzara®**.** This proposition is to request the inclusion of Olumiant®. **Olumiant® (baricitinib)** is a Janus kinase inhibitor indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis, and is taken orally once daily. A class comparison chart and package inserts are included for the committee's review. **Public Comment:** None. **Committee Discussion:** Dr. Magee moved to approve. Dr. Wallace seconded the motion. The motion carried unanimously.
III. New Business **J. Immunomodulation Agents – Ulcerative Colitis: New Agent – (Xeljianz®)**	Taylor Gill, Pharm.D., BCPS, AAHIVP	**Background:** This class was first introduced to the PDL committee as a new class in March 2017. This class was most recently reviewed in June 2017 for the inclusion of Entyvio® and Simponi®. The requested inclusion presented for review today is for **Xeljanz® (tofacitinib),** which is a Janus kinase inhibitor that has a newly approved indication for ulcerative colitis. It is a 10-mg tablet taken twice daily. A class comparison chart and package inserts are included for the committee's review. **Public Comment:** None. **Committee Discussion:** Dr. Sweet moved to approve. Dr. Wallace seconded the motion. The motion carried unanimously.

Item	Facilitator (s)	Notes
III. New Business **K. Insulin – Short Acting and Intermediate Acting - New Agent – (Admelog®, Admelog Solostar®)** **III. New Business**	Taylor Gill, Pharm.D., BCPS, AAHIVP	**Background:** The Insulin – Short Acting and Intermediate Acting class was first introduced to the PDL committee as a new class in June 2003. This class was most recently reviewed in March of 2018 and is being requested today for inclusion of **Admelog® SoloStar®** and **Admelog® vial**. **Admelog® (insulin lispro injection)** is a rapid-acting human insulin analog indicated to improve glycemic control in adults with type 2 diabetes and children (≥ 3 years of age) and adults with type 1 diabetes. A class comparison chart and package inserts are included for the committee's review. **Public Comment:** Jason Lurk of Novo Nordisk highlighted attributes of Fiasp and Fiasp Flextouch. **Committee Discussion:** Dr. Wallace moved to approve. Dr. Sweet seconded the motion. The motion carried unanimously.
III. New Business **L. Opioids – Short Acting – Class Review – New Agent: (RoxyBond™)**	Taylor Gill, Pharm.D., BCPS, AAHIVP	**Background:** The Short-Acting Opioids class was first introduced to the PDL committee as a new class in December 2017 and was most recently reviewed in March 2018 for the inclusion of Apadaz™. This proposition requests the inclusion of **Roxybond™**, which is an immediate-release formulation of oxycodone available as an abuse-deterrent tablet. A class comparison chart and package inserts are included for the committee's review. **Public Comment:** None **Committee Discussion:** Dr. Hedden moved to approve. Dr. Wallace seconded the motion. The motion carried unanimously.

Item	Facilitator (s)	Notes
III. New Business **M. Bowel Prep Agents – New Class – (Clenpiq®, Gavilitye-C®, Gavilyte-G®, Gaviltye-N®, GoLYTELY®, Moviprep®, NuLYTELY®, OsmoPrep®, PEG-3350**	Taylor Gill, Pharm.D., BCPS, AAHIVP	**Background:** The Bowel Prep Agents class is presented today for approval and inclusion to the PDL. These agents work by drawing water into the intestine through an osmotic effect. This leads to distension and stimulation of colonic peristalsis. These products are indicated for bowel cleansing prior to colonoscopy. A class comparison chart and package inserts are included for the committee's review. **Public Comment:** None. **Committee Discussion:** Dr. Haneke moved to approve. Dr. Wallace seconded the motion. The motion carried unanimously**.**
III. New Business **N. Class Name Change Request – Non-steroidal Atopic Dermatitis to Topical Immunomodulators**	Taylor Gill, Pharm.D., BCPS, AAHIVP	**Background:** The Non-Steroidal Atopic Dermatitis class was first introduced to the PDL committee in June 2018 for the inclusion of Elidel®, Eucrisa® and Protopic®. This proposition requests to change the name of the class to Topical Immunomodulators to match the Topical Immunomodulator prior authorization criteria that was approved by the DUR Board in July 2018. **Public Comment:** None **Committee Discussion:** Dr. Sweet moved to approve. Dr. Wallace seconded the motion. The motion carried unanimously.

Item	Facilitator (s)	Notes
IV. Open Public Comment	Taylor Gill, Pharm.D., BCPS, AAHIVP	Ms. Grant commented that in the future, new classes will have supporting data. The PDL meeting time changes from the past times are updated on the KDHE website. She reported some data on Pulmonary Hypertension Agents - 131 patients, 643 claims at $3 million, which saved the State money bringing that class to the PDL. The Hereditary Angioedema Agents and the Opioid Antagonist Classes were previously approved, but the State has not added those classes to the PDL at this time. The Ophthalmic Anti-inflammatory/Mass Cell Stabilizer class was left as one class and not divided. Dr. Wallace inquired as to why Suboxone came out with a generic, but it is no longer available. There was discussion as to what options the providers would have for drug selection. Dr. Wallace asked the rest of the committee if they had a need for the disc that the State sends in the mail. All pertinent items are emailed to the committee members and the disc only served to include the lengthy package inserts. The committee agreed that the State did not need to mail out the discs, but to make sure that all meeting documents would be sent via email to the committee prior to the meeting.
V. Adjourn	Taylor Gill, Pharm.D., BCPS, AAHIVP	Dr. Gill adjourned the meeting at 10:55 a.m.

September 2018 Consent Agenda Item List				
This PDL option/process was approved 09/13/2017 by the PDL Committee and 10/11/2017 by the DUR Board.				
Drug Proposed - Consent Agenda Item	**Compare Drug**	**Supporting information**	**Meeting Date listed on the PDL Agenda**	**PDL Committee Approval Yes/No**
Aczone 7.5% Gel	Aczone 5% gel		9/12/2018	
Avita Gel	Avita cream		9/12/2018	
Cleocin T- Swabs	Cleocin T gel		9/12/2018	
Clindacin PAC kit	Clindacin-P swab		9/12/2018	
Differin Lotion & Solution	Differin gel		9/12/2018	
Ditropan Liquid		Approved March 2017 PDL meeting.	3/08/2017 9/12/2018	
Evekeo		Approved March 2017 PDL meeting.	3/08/2017 9/12/2018	
Fosamax Liquid	Fosamax		9/12/2018	
Retin-A 0.01% Gel	Retin A cream		9/12/2018	
Sumadan XLT	Sumadan		9/12/2018	